Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2012
Variation in reported neonatal group B streptococcal disease incidence in developing countriesAlemnew F Dagnew, Marianne C Cunnington, Queen Dube, et al.
Drug Safety|June 11, 2021
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six TrialsMarta López-Fauqued, Maribel Co-van der Mee, Adriana Bastidas, et al.
PLOS Global Public Health|November 8, 2023
Data-driven epidemiologic approach to conducting site feasibility for a global phase III tuberculosis vaccine clinical trialWai-Ling Mui, Falgunee K Parekh, Ashley S Tseng, et al.
BMC Research Notes|August 9, 2012
Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birthAlemnew F Dagnew, Jemal Hussein, Markos Abebe, et al.
Vaccine|May 12, 2026
Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccineAlemnew F Dagnew, Robert Noble, Amy Cinar, et al.
Trials|January 12, 2018
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic areaJemal Hussein, Martha Zewdie, Lawrence Yamuah, et al.
The Lancet. HIV|July 4, 2025
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trialAlemnew F Dagnew, Linda L Han, Kogieleum Naidoo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2014
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adultsHoan Jong Lee, Moon-Hyun Chung, Woo Joo Kim, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
The Lancet. Microbe|July 4, 2024
Implications of subclinical tuberculosis for vaccine trial design and global effectGavin J Churchyard, Rein M G J Houben, Katherine Fielding, et al.
Pageof 3